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AbstrACt
Introduction unCoVer—Unravelling data for rapid 
evidence- based response to COVID- 19—is a Horizon 
2020- funded network of 29 partners from 18 countries 
capable of collecting and using real- world data (RWD) 
derived from the response and provision of care to patients 
with COVID- 19 by health systems across Europe and 
elsewhere. unCoVer aims to exploit the full potential of this 
information to rapidly address clinical and epidemiological 
research questions arising from the evolving pandemic.
Methods and analysis From the onset of the COVID- 19 
pandemic, partners are gathering RWD from electronic 
health records currently including information from over 
22 000 hospitalised patients with COVID- 19, and national 
surveillance and screening data, and registries with 
over 1 900 000 COVID- 19 cases across Europe, with 
continuous updates. These heterogeneous datasets will 
be described, harmonised and integrated into a multi- 
user data repository operated through Opal- DataSHIELD, 
an interoperable open- source server application. 
Federated data analyses, without sharing or disclosing 
any individual- level data, will be performed with the 
objective to reveal patients’ baseline characteristics, 
biomarkers, determinants of COVID- 19 prognosis, safety 
and effectiveness of treatments, and potential strategies 
against COVID- 19, as well as epidemiological patterns. 
These analyses will complement evidence from efficacy/
safety clinical trials, where vulnerable, more complex/
heterogeneous populations and those most at risk of 
severe COVID- 19 are often excluded.
Ethics and dissemination After strict ethical 
considerations, databases will be available through a 
federated data analysis platform that allows processing of 
available COVID- 19 RWD without disclosing identification 
information to analysts and limiting output to data 
aggregates. Dissemination of unCoVer’s activities will 
be related to the access and use of dissimilar RWD, as 
well as the results generated by the pooled analyses. 
Dissemination will include training and educational 
activities, scientific publications and conference 
communications.
IntroduCtIon
The outbreak of COVID- 19, caused by SARS- 
CoV- 2, was declared a public health emer-
gency of international concern by the WHO 
strengths and limitations of this study
 ► The unCoVer (Unravelling data for rapid evidence- 
based response to COVID- 19) network includes a 
sizeable number of partners that will exploit the full 
potential of real- world data derived from the pro-
vision of care to patients with COVID- 19 by health 
systems across Europe and elsewhere.
 ► With the availability of international harmonised 
real- world data provided by the unCoVer network, 
a large amount of information on patients with 
COVID- 19 will be studied to better understand as-
pects of pathophysiology, progression and treat-
ment, and the epidemiological patterns of this novel 
disease, as well as to grasp the less understood, and 
potentially unearthed, risk factors associated with 
COVID- 19 severity.
 ► The development and deployment of a federated 
data platform for combined analysis meet patients’ 
data protection principles and comply with ethical 
standards, including general data protection reg-
ulation and national data privacy legislation, while 
allowing for advanced analytics.
 ► Continuous process evaluation will be carried out 
throughout the project life to identify limitations and 
barriers to the harmonised use of data, and simulta-
neously providing advice on improving data systems 
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on 30 January 2020 and a pandemic on 11 March 2020. 
Despite the deployment of public health measures, such 
as restrictions of movements and gathering, personal 
protection, as well as massive vaccination campaigns, 
the coronavirus is still largely affecting mortality and 
morbidity worldwide, including persisting symptoms after 
the infection, what has now been termed post- COVID- 19 
condition.1 Early epidemiological data on COVID- 19 
showed a higher risk of severe disease among older 
individuals, in particular those with chronic respiratory, 
cardiometabolic and other chronic diseases, including 
mental disorders and immunosuppressed individuals.2–4 
While the pathogenesis of certain chronic diseases predis-
poses to serious COVID- 19 outcomes,5 other factors such 
as common chronic medications might also increase this 
risk due to interaction between SARS- CoV- 2 infection and 
the complex metabolic pathways.6 7 Also, common disease 
risk factors such as smoking and overweight/obesity have 
been identified as key predictors of hospitalisation and 
critical illness, even in young adults with no underlying 
conditions.8 9
While the pandemic is evolving and countries are 
adapting their health systems to new phases of preventive 
measures, the research community is trying to fully eluci-
date the transmission and progression of the infection, as 
well as the most effective ways of treating and preventing 
new cases in preparation for any new waves, particularly 
due to new variants of SARS- CoV- 2. The multidimen-
sional and dynamic nature of the inter- related factors 
associated with individual responses to the SARS- CoV- 2 
infection and the diversity of long- term complications 
require a multidisciplinary research approach to unravel 
the natural history of this pandemic. Responding to the 
COVID- 19 pandemic in real time required a colossal 
effort from health systems worldwide and across Europe, 
where several countries have been severely affected. As 
a result, a wealth of data have been accumulated as part 
of health systems’ efforts to fight COVID- 19. These real- 
world data (RWD) reflect the impact of COVID- 19 on 
patients’ health and characterise the protocols of health-
care in different health system settings. These close- to- 
reality data allow for studies into patients’ characteristics, 
determinants of disease prognosis and effectiveness 
of potential strategies against COVID- 19 in real- world 
settings. They also complement findings from ongoing 
efficacy/safety clinical trials, where vulnerable/hetero-
geneous populations and those most at risk of severe 
COVID- 19 are often excluded. Harmonisation of data 
from different sources allows for comparison across 
health systems and improves patients’ characterisation 
using the wider heterogeneity of information. Still, 
to date, these RWD sources related to COVID- 19 have 
been exploited in a limited way and for specific ques-
tions; hence, there is an untapped opportunity to exploit 
the full potential of these data through identification, 
harmonisation and big data analysis.
objectives
The unCoVer (Unravelling data for rapid evidence- 
based response to COVID- 19) network aims to provide 
a research platform for the expert use of RWD by 
bringing together complementary data and medical and 
scientific expertise to address the still urgent questions 
regarding the determinants of COVID- 19 prognosis to 
inform more effective medical and public health strate-
gies. Specifically, the network aims to facilitate access to 
otherwise scattered RWD sources, and hereby provide 
opportunities for enhanced risk characterisation and 
robust risk prediction algorithms, tackling the current 
pandemic and eventually any future epidemics. This 
approach should lead to control measures that will even-
tually relieve the pressure on health systems, improve 
patient prognosis especially among those more vulner-
able (eg, chronic patients, immunosuppressed individ-
uals and population subgroups with limited access to 
healthcare, among others) and mitigate the burden of 
COVID- 19. The following are the specific objectives of 
unCoVer:
 ► To bring together European and international exper-
tise and data to synchronise collaborative research 
efforts in addressing the ongoing COVID- 19 pandemic 
in a common platform.
 ► To continuously monitor, identify and facilitate access 
and use of COVID- 19- related RWD to fully exploit the 
potential of this routinely collected information, as a 
reflection of common medical practices.
 ► To identify data gaps and marginalised populations 
to proactively seek synergies with complementary 
existing and planned clinical databases related to 
COVID- 19.
 ► To provide a platform for the use of dissimilar data 
sources capable of streamlining ethical and legal 
aspects and anticipating the needs for data harmo-
nisation by innovative computational resources and 
integrated information for enhanced impact.
 ► To bring together expertise on the use of advanced 
computational, epidemiological and biostatistical 
methods to handle heterogeneous and multilay-
ered information to facilitate rapid queries and data 
outputs related to SARS- CoV- 2 infection, underlying 
drivers of COVID- 19 prognosis, the safety and effec-
tiveness of treatments, and the sequelae as well as the 
impact of COVID- 19 on health system resources.
 ► To broadcast the use and results of the platform to 
attract new partners and to pursue complementarity 
with existing similar networks in Europe and interna-
tionally to save lives and optimise resources.
MEthods And AnAlysIs
unCoVer is conceptualised as a functional network of part-
ners capable of harvesting and analysing RWD derived 
from the response and provision of care to patients by the 
health systems across Europe and other countries, such 
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Figure 1 Geographical distribution of the unCoVer network (Belgium, Bosnia and Herzegovina, Brazil, Colombia, Croatia, 
Greece, Ireland, Italy, Luxembourg, Norway, Portugal, Romania, Slovakia, South Korea, Spain, Turkey, UK and USA). unCoVer, 
Unravelling data for rapid evidence- based response to COVID- 19.
setting
unCoVer comprises 29 partners from 25 institutions 
in the European Union (EU) and 4 non- EU partners 
representing 18 countries, namely Belgium, Bosnia and 
Herzegovina, Brazil, Colombia, Croatia, Greece, Ireland, 
Italy, Luxembourg, Norway, Portugal, Romania, Slovakia, 
South Korea, Spain, Turkey, UK and USA (figure 1). Part-
ners provide data mostly from front- line hospitals but also 
from national health agencies, registries and investiga-
tor- led observational studies, and represent complemen-
tary scientific and medical fields, as well as expertise in 
research ethics, data management and statistical model-
ling. unCoVer, thus, works as a functional network 
bridging clinical expertise and data analytics, intending 
to exploit the full potential of routine healthcare data 
already collected from patients during the pandemic. 
The set- up of the network therefore relies on a contin-
uous iteration process between (1) clinical partners, who 
will guide the development of research questions needed 
to improve patients’ care and inform public health strate-
gies; and (2) epidemiologists and analytical experts, who 
will operationalise the research questions with advanced 
data processing, analysis and simulation tools capable of 
generating innovative solutions. The work of the network 
is further supported by three external advisory boards 
(figure 2) that provide expert counselling concerning 
the relevance of medical research and findings (External 
Advisory Board), data protection (Data Protection and 
Ethics Advisory Board, DP- EAB) and stakeholder involve-
ment (Societal and Regulatory Advisory Board, SRAB).
databases
unCoVer facilitates access to observational data for 
secondary analyses. These data are largely collected for 
non- research purposes, RWD, and refer to data gener-
ated during patient encounters with the health systems 
which have established information technology protocols 
and tools for retrieving and storing information about 
the healthcare provided. To date, the unCoVer network 
incorporates 16 databases of electronic medical records 
from 10 different countries, 6 national registries, 4 obser-
vational cohorts and 2 databases on population screening 
(table 1). The data available to unCoVer have informa-
tion on hospitalisation of patients with COVID- 19 with at 
least two time points of data collection: at admission and 
at discharge. In addition to demographics and clinical/
epidemiological data, other types of data such as biospe-
cimens, imaging data, social network- related/contact- 
tracing- related data, movement- related data and mental 
health data are also available but with limited access. Clin-
ical/epidemiological data include case report forms at 
the patient’s admission (ie, date of symptom onset and/
or admission, signs and symptoms at admission, labora-
tory results, preadmission medication, comorbidities and 
risk factors), during hospitalisation (ie, signs and symp-
toms, laboratory results, supportive treatment, admis-
sion to intensive care unit) and at discharge (ie, date of 
discharge, outcome, as well as medication and complica-
tions) (online supplemental table 1).
structure and activities
Three blocks of activities, grouping work packages (WPs), 
were designed to build a functional network over a period 
of 36 months from November 2020 onwards, and aim to 
facilitate the flow of information for rapid assessment of 
research questions.
Block 1: definition, design and data harvesting
This first block forms the architectural foundation and 
the core of the unCoVer network. In order to provide 
a comprehensive repository of available data, WP1 
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Figure 2 Management structure of the unCoVer network. unCoVer, Unravelling data for rapid evidence- based response to 
COVID-19.
a standardised way, including a common codebook that 
specifies the harmonised variables, with standardised 
variable names and data format and labels, and range of 
plausible values, in preparation for data harmonisation 
and validation processes, that is, the key for the develop-
ment of a unified pool of data for analyses. In parallel, 
and acknowledging the sensitive nature of health data, 
and personal information compliance with ethical and 
legal aspects, a checklist for assessing the risks involved in 
data processing is implemented by WP2 ‘Ethics and Data 
Protection’, with due consideration to legal and regula-
tory issues concerning data protection, privacy and infor-
mation security. The checklist includes questions on the 
nature of the data (eg, clinical data, hospital records or 
publicly available data, personal data, data collected in 
vulnerable groups, availability of follow- up data), informed 
consent (eg, explicit consent or assent obtained), data 
protection (eg, data protection officer identified and 
data protection impact assessment completed), ethical 
approval (obtained or pending), data privacy protection 
(eg, anonymisation vs pseudonymisation, data minimisa-
tion), and data transfer and use (data transfer agreement 
needed, name of the data controller, data processor, 
joint data controller if applicable, and whether interna-
tional transfer outside EU). Each data provider within 
the network populates this checklist, which is reviewed 
on a case- by- case basis by the unCoVer research ethics 
expert team together with the independent DP- EAB, and 
accordingly informed decisions on risk mitigation are 
taken. In short, WP2 ensures that general data protection 
regulation (GDPR) or equivalent guidelines are adhered 
to during the data processing activity. Once a data set is 
categorised as low risk, it will be available to proceed with 
subsequent steps (online supplemental table 2).
For the secure multi- party computation of unCoVer 
data, WP3 ‘Data Harmonization’ developed an infra-
structure based on Opal V.4.1 (OBiBa suite; Maelstrom 
Research, Montreal, Canada) to facilitate interoperability 
of the data, including data management, harmonisation 
and dissemination in a secured environment.10 The Opal 
server application provides the necessary key features 
for data encryption and decryption managed through 
public key infrastructure, as well as participant identifier 
management and user authentication/authorisation for 
access via a rights and roles management with username/
password. The following are the steps to achieve data 
harmonisation and secured data sharing and use: (1) set 
up the Opal server for each data provider and import rele-
vant data sets; (2) configure a harmonised data descrip-
tion in each Opal server; and (3) run distributed queries 
on harmonised data sets through the DataSHIELD appli-
cation, which enables individual- level data analyses across 
multiple Opal servers without sharing and disclosing any 
individual- level data (figure 3). Thus, by using computa-
tional power and standardising dissimilar information, 
while complying with ethical and legal requirements, a 
data repository of anonymised and harmonised COVID- 19 
RWD will be made available for secured data analyses.
Block 2: analytical development, data use and demonstration
The broad range of medical, public health and research 
expertise available within the unCoVer network is at the 
heart of WP4 ‘Data analysis and Outcomes’, dedicated to 
unCoVer findings from the data acquired to maximise 
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Figure 3 Secure multi- party computation of unCoVer data based on Opal- DataSHIELD infrastructure. unCoVer, Unravelling 
data for rapid evidence- based response to COVID-19.
Abbreviation: DB, database.
this block aim to facilitate and streamline rapid response 
to identified research gaps using the unCoVer infrastruc-
ture developed in block 1. With the availability of cross- 
national harmonised RWD within the unCoVer network, 
a large amount of hospitalised and discharged patients 
who had COVID- 19 will be studied in depth, together 
with complementary epidemiological data, to understand 
the pathophysiology, progression, treatment (long- term) 
complications and (less frequent) risk factors for early 
prevention of this novel disease, as well as to grasp the 
cross- national heterogeneity of the COVID- 19 burden. To 
this end, an analytical toolbox, including both traditional 
statistical methods and machine learning techniques and 
a Bayesian estimation framework, will be developed for 
identifying relationships between early clinical and diag-
nostic profiles and the future course of the infection, and 
for a detailed clinical and epidemiological characterisa-
tion of patients with COVID- 19, being able to generate 
patients’ risk classification and risk prediction. The appli-
cation of this toolbox in real patient data, available within 
the unCoVer network, will then allow uncovering real- 
world insights that would support policies and protocols 
for optimisation of health resources of the hospital and 
critical care. Therefore, the activities of this block will be 
related to the iterative trial use of the Opal server and 
the toolbox by end users (ie, data analysts), as well as the 
lessons learnt and potentially preparing actions for the 
sustainability of the unCoVer platform, including the 
repository and toolbox.
Block 3: project management, communication and exploitation
The outputs of the network, including the scientific and 
technological knowledge and outcomes, provided by the 
previous two blocks, are streamlined through scientific 
publications, training and educational activities, organi-
sation and participation in events, among others, steered 
by WP5 ‘Communication, Exploitation & Dissemination’. 
This last block is also dedicated to maintaining the func-
tional network both internally and externally, and with 
special attention to the management of intellectual prop-
erty by using best practices in project coordination, as 
outlined in WP6 ‘Coordination’. Concerning this, the 
unCoVer organisation structure works under a consor-
tium agreement signed by all partners and includes the 
following key bodies within the consortium and manage-
ment structure (figure 2): a steering committee formed 
by the principal investigators of the 29 partner institu-
tions at the decision- making level; and a general assembly 
(GA), involving WP leaders, which manages the network 
and coordinates WP and tasks leaders, assisted also by a 
management support team to reinforce partners’ repre-
sentation. An internal Exploitation and Dissemina-
tion Committee (EDC) also collaborates in the overall 
management of the GA. Finally, the project coordinators 
communicate with the sponsor and facilitate crosstalk 
between the network and external advisory boards.
EthICs And dIssEMInAtIon
The unCoVer study has been approved by the Institu-
tional Review Board of the Institute of Tropical Medi-
cine in Antwerp (IRB/RR/ac/151, protocol number 
1524/21). Ethical aspects are of utmost importance 
in unCoVer. On the project start date, the roles and 
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Figure 4 Data management process of the COVID- 19- related data available within the unCoVer network. DPIA, data 
protection impact assessment; unCoVer, Unravelling data for rapid evidence- based response to COVID- 19; WP, work package.
described, including the selection procedure of 
the board members and its final composition and 
mandate. A ‘scoping exercise’ was also conducted 
across the network to ensure that all partners are 
aware of the common obligations in terms of data 
processing activities using health or health- related 
data according to European and international guide-
lines. Moreover, to be compliant with the GDPR and 
meet the ethics requirements, the unCoVer network 
will follow the data processing steps represented in 
figure 4, in the following sequence:
 ► The unCoVer master checklist of data processing 
activities in network partners is circulated within 
the network to be completed by the data providers, 
and data providers are required to provide the 
supporting documentation of each indicator of this 
list, such as informed consents, ethical approvals 
and data protection impact assessments. This infor-
mation is processed by the research ethics team, 
responsible for categorising the data sets into three 
different categories: low, medium or high data 
privacy risk.
 ► Data sets categorised as ‘low- risk’ will be available to 
proceed with the harmonisation process and there-
fore Opal- DataSHIELD servers will be installed. Within 
Opal, the patient identifiers will be separated from the 
patient study data by employing two databases: (1) the 
identifier (ID) database, which stores patient identifiers 
accessible to the data provider only; and (2) the study 
database, which stores pseudoanonymised patient data to 
be used for data analyses accessible, through code only, 
to data analysts. The ‘medium-’ and ‘high- risk’ datasets 
will be subject to further review and requirements before 
harmonisation processes.
 ► Finally, the installation of the servers will allow the 
consortium to analyse the available RWD through 
an anonymisation layer to answer the preiden-
tified research questions. The system also facili-
tates the definition of analytical projects and the 
specific databases and/or variables that will be 
used for a specific project. As a rule, all output of 
data analytics will be restricted to the presenta-
tion of data aggregates or to line listing deprived 
of personal identifiers so that the identity of the 
study patient cannot be deduced (no backward 
identification).
To maximise the unCoVer network’s output, dissem-
ination and exploitation strategies, as planned by the 
EDC and advised by the SRAB, that is, a non- executive 
consulting substructure composed of several key 
stakeholders from the regulatory, governance, civil 
society level and patients’ public initiatives, will be 
segmented according to the network block activities, 
the potential users and the most adequate channels 
of dissemination and interaction with potential users. 
The website ( uncover- eu. net/), social media accounts 
(Twitter @uncoverEU, LinkedIn, YouTube) and the 
project newsletter will be the channels to reach all 
partners and stakeholders of unCoVer, both devoted 
to providing regular updates on project activities 
and announcing upcoming milestones and events. 
The website will serve as a repository of the project 
goals and activities and deliverables in an easy- to- 
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and expert documents hosted for access by the part-
ners or stakeholders.
PAtIEnt And PublIC InvolvEMEnt
The unCoVer network has been designed to facilitate 
interactions and enhance outreach to COVID- 19 stake-
holders included in external advisory boards, as well as 
prominent WPs on dissemination activities, which include 
but are not limited to the following:
 ► Scientific community. To contribute to the body of 
knowledge in the field, two types of publications in 
peer- reviewed journals under open- access schemes 
are foreseen: the unCoVer network publications, 
that is, for implementation and/or application of the 
unCoVer platform as a whole; and the unCoVer part-
ners publication, that is, for specific collaborations 
between two or more unCoVer partners. In addition to 
both types of scientific publications, jointly organised 
workshops, virtual trainings and virtual conferences 
will be instrumental channels for the dissemination 
of the unCoVer activities and results to the scientific 
community. In such a yearly organised workshop, the 
application of the unCoVer repository and toolbox 
will be presented and expert feedback will be sought 
for further improvement. These activities of dissem-
ination to the scientific community will result in 
overall awareness and international recognition of 
the unCoVer network, simultaneously strengthening 
the visibility and competitiveness of the institutions 
involved as centres of excellence.
 ► European platforms and data- driven initiatives. Coop-
eration with other European projects dedicated to 
COVID- 19 data sharing such as Orchestra ( orchestra- 
cohort. eu), Synchros ( synchros. eu), Dragon ( imi. 
europa. eu/ projects- results/ project- factsheets/ 
dragon), RecodID ( recodid. eu) and EC- COVID- 19 
Data Platform ( covid19dataportal. org), as well as 
large networks such as the European Burden of 
Disease Network ( burden- eu. net) and initiatives on 
data sharing infrastructures such as the Population 
Health Information Research Infrastructure ( phiri. 
eu), will be established for the co- organisation of 
dissemination events along with seeking alignment 
and synergies to avoid duplication of efforts.
 ► Policymakers. The accumulated prior experience and 
contact networks in the regulatory, policymaking 
framework of several members of the unCoVer 
network will be used to ensure that the work and 
output created can reach regulatory entities and 
policymakers, thus contributing to the impact of 
the project on the decision- making process. This 
appears relevant as the unCoVer network is willing to 
merge different sources of medical data with social, 
economic, mental and geographical data with the 
potential to identify highly tailored profiles of risk for 
community prevention programmes and educational 
goals in different countries.
 ► Engagement with key stakeholders. Results from the 
project will be further disseminated through involve-
ment with societal, regulatory and administrative part-
ners, as ensured by the external advisory boards to the 
network, with the goal to warrant the project’s impact 
according to stakeholders’ needs and expectations.
 ► General public. To maximise awareness of unCoVer 
among the general public, the project activities and 
milestones will be broadcasted via social media.
 ► Patient associations and clinicians. Given the fore-
seen impact of unCoVer’s output, patient associa-
tions and clinicians are identified as end users that 
benefit from the data- oriented results, and subse-
quently these can be translated to them via semi-
nars, lectures and infographics as made available on 
the project website, among others.
dIsCussIon
During the early phases of the pandemic, the unCoVer 
network grew organically from initial partnerships 
accessing individual databases to answer pressing 
COVID- 19 questions. These initial collaborations soon 
recognised the need for accessing extended informa-
tion to develop more robust analytical models and 
outputs. To this end, the concept of unCoVer origi-
nates in the shared interest of its partners to synchro-
nise the research efforts needed for exploiting and 
valorising the underutilised and inexpensive RWD in 
addressing the ongoing COVID- 19 pandemic. Within a 
limited duration of 2 years, efforts of the first year were 
mainly focused on the organisation of the network and 
the set- up of a collaborative federated data infrastruc-
ture, accounting for local, national and international 
ethical and data protection guidelines and streamlining 
procedures for data processing activities, including 
data identification, sharing, harmonisation, validation 
and analytics. Entering the second year, the unCoVer 
network aims to demonstrate the usability of the devel-
oped infrastructure on the combined use of RWD to 
address clinical and epidemiological research questions 
related to the COVID- 19 pandemic, both revising ques-
tions answered with limited data sets and new questions 
arising from the evolving pandemic. The unCoVer 
network, therefore, serves as a proof of concept for 
building a federated data infrastructure facilitating 
data interoperability in a secured environment, while 
complying with ethical and data protection guidelines. 
Moving forward, the established framework of unCoVer 
provides valuable input for the use of complementary 
RWD with robust methodologies at hand for the still 
ongoing current pandemic and future pandemics.
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